Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | GALR3 | O60755 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30374539 | 1.00 | DGAT1 (0.50) | DGAT1PTGDR2MAOAALDH1A1NPC1 | |
| SCHEMBL6103986 | 0.96 | DGAT1 (0.47) | DGAT1PTGDR2MAOAALDH1A1NPC1 | |
| SCHEMBL29820628 | 0.83 | DGAT1 (0.66) | DGAT1PTGDR2MAOAALDH1A1NPC1 | |
| SCHEMBL8204 | 0.83 | DGAT1 (0.66) | DGAT1PTGDR2MAOAALDH1A1NPC1 | |
| SCHEMBL16960361 | 0.83 | DGAT1 (0.44) | DGAT1PTGDR2MAOAALDH1A1NPC1 | |
| SCHEMBL30722862 | 0.81 | KDM4E (0.59) | DGAT1ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL2554 | 0.81 | KDM4E (0.59) | DGAT1ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL30864269 | 0.80 | MAOA (0.53) | DGAT1PTGDR2MAOAALDH1A1CES2 | |
| SCHEMBL351693 | 0.79 | DGAT1 (0.71) | DGAT1ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL181200 | 0.79 | ALDH1A1 (0.52) | DGAT1ALDH1A1NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 669 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010910-A | Biazacycloalkane Menin-MLL protein inhibitor, pharmaceutical composition and application thereof | 赛诺哈勃药业（成都）有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12516065-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4665332-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4638438-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | Xinthera, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12390462-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12391695-B2 | PRMT5 inhibitors | LUPIN LIMITED (IN) | 2025-08-19 | — | — | US | disclosed |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| US-20030176314-A1 | Compounds for the treatment of pain | H. LUNDBECK A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003026657-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-5849775-A | Substituted benzoylguanidines process for their preparation, their use as a medicament or diagnostic, and pharmaceutical containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
| US-5679712-A | ANTIARRHYTHMIA AGENTS, TREATMENT OF CARDIOVASCULAR, NERVOUS SYSTEM DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | disclosed |
| US-5631293-A | CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | DGAT1 3473/4885PTGDR2 2313/4885MAOA 3268/4885 |
| US-20030176314-A1 | Compounds for the treatment of pain | NPFFR2, NPFFR1, OPRL1 | DGAT1 2370/4885PTGDR2 25/4885MAOA 2697/4885 |
| US-12391695-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | DGAT1 2667/4885PTGDR2 4807/4885MAOA 3209/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | DGAT1 3473/4885PTGDR2 2313/4885MAOA 3268/4885 |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | DGAT1 2621/4885PTGDR2 418/4885MAOA 1752/4885 |
| US-12390462-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | DGAT1 2414/4885PTGDR2 550/4885MAOA 131/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | DGAT1 3715/4885PTGDR2 4161/4885MAOA 3009/4885 |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | XBP1, DDIT3, HSP90B1 | DGAT1 1052/4885PTGDR2 2416/4885MAOA 4838/4885 |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | NPFFR1, NPFFR2, SSTR3 | DGAT1 2307/4885PTGDR2 620/4885MAOA 1351/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | DGAT1 2701/4885PTGDR2 1132/4885MAOA 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.